98%
921
2 minutes
20
Background: Tuberculosis incidence is increasing in Latin America, where the incarcerated population has nearly quadrupled since 1990. We aimed to quantify the impact of historical and future incarceration policies on the tuberculosis epidemic, accounting for effects in and beyond prisons.
Methods: In this modelling study, we calibrated dynamic compartmental transmission models to historical and contemporary data from Argentina, Brazil, Colombia, El Salvador, Mexico, and Peru, which comprise approximately 80% of the region's incarcerated population and tuberculosis burden. The model was fit independently for each country to incarceration and tuberculosis data from 1990 to 2023 (specific dates were country dependent). The model does not include HIV, drug resistance, gender or sex, or age structure. Using historical counterfactual scenarios, we estimated the transmission population attributable fraction (tPAF) for incarceration and the excess population-level burden attributable to increasing incarceration prevalence since 1990. We additionally projected the effect of alternative incarceration policies on future population tuberculosis incidence.
Findings: Population tuberculosis incidence in 2019 was 29·4% (95% uncertainty interval [UI] 23·9-36·8) higher than expected without the rise in incarceration since 1990, corresponding to 34 393 (28 295-42 579) excess incident cases across countries. The incarceration tPAF in 2019 was 27·2% (20·9-35·8), exceeding estimates for other risk factors like HIV, alcohol use disorder, and undernutrition. Compared with a scenario where incarceration rates remain stable at current levels, a gradual 50% reduction in prison admissions and duration of incarceration by 2034 would reduce population tuberculosis incidence by over 10% in all countries except Mexico.
Interpretation: The historical rise in incarceration in Latin America has resulted in a large excess tuberculosis burden that has been under-recognised to date. International health agencies, ministries of justice, and national tuberculosis programmes should collaborate to address this health crisis with comprehensive strategies, including decarceration.
Funding: National Institutes of Health.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602220 | PMC |
http://dx.doi.org/10.1016/S2468-2667(24)00192-0 | DOI Listing |
Indian J Dermatol
September 2025
From the Department of Public Health Sciences, Indian Institute of Public Health Gandhinagar, Gandhinagar, Gujarat, India.
Background: Skin diseases affect a significant portion of the population, with potentially severe consequences on physical and psychosocial well-being. However, skin disorders are often overlooked in healthcare discussions and funding allocation, despite their substantial impact on patients' lives.
Aims And Objectives: The objective of this study was to investigate the psychosocial and psychiatric impact of chronic dermatological disorders among patients.
Evol Med Public Health
July 2025
National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Shenzhen, China.
Background And Objectives: Drug resistance is a major contributor to tuberculosis (TB) deaths worldwide. Understanding the dynamics of in-host evolution of (MTB) drug resistance can help to improve treatment success rates.
Methodology: The microevolution of drug-resistant MTB was studied in three patients with long-standing, extensively drug-resistant TB (XDR-TB) by analyzing whole genome sequences of serial isolates collected during treatment.
Lancet Infect Dis
September 2025
The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis.
Methods: Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries.
Ther Innov Regul Sci
September 2025
Fiocruz Brasilia, ColLaboratory of Science, Technology, Innovation and Society (CTIS), Brasilia, DF, Brazil.
Purpose: To identify and review scientific evidence from experimental studies utilizing unmanned aerial vehicles (UAVs) to transport samples for the diagnosis of COVID-19 and tuberculosis (TB). This exploratory study aims to support the future development of UAVs for transporting biological samples within the Brazilian Unified Health System (SUS).
Methods: This scoping review defined its eligibility criteria using the PECO acronym, focusing on: Population: biological samples for diagnosing COVID-19 or TB; Exposure: UAV transportation; Comparator: land transportation; Outcomes: Cost, effectiveness, methods for sample preservation, flight parameters (time, altitude, speed, distance), and quality of transported samples.
Ann Vasc Surg
September 2025
Department of Oncology, Anhui Medical University Clinical College of Chest &Anhui Chest Hospital, Hefei, 230022, People's Republic of China.
Objective: This study aimed to characterize the association between pulmonary embolism (PE) onset and various anti-tumor therapeutic approaches in patients with lung cancer, with the goal of identifying potential high-risk populations.
Methods: A retrospective analysis was conducted on clinical records from 2019 to 2025, among the 84,000 inpatients with lung cancer, 106 patients developed PE during hospitalization for anti-tumor treatment, who were confirmed using spiral computed tomography (CT) or pulmonary angiography per CTS (2018) and NEJM (2010) criteria. Data were collected on patient demographics, cancer staging, treatment type, and time to PE onset.